Swedish biopharmaceutical company Sobi (STO: SOBI), which focuses on rare diseases, said on Tuesday that the European Commission has approved Tryngolza (olezarsen) for adults with severe hypertriglyceridaemia (sHTG).
It is the first and only RNA-targeted therapy authorised in the EU for this group.
The decision follows an early positive opinion from the Committee for Medicinal Products for Human Use in October, and widens the existing marketing authorisation for Tryngolza, which already covers familial chylomicronaemia syndrome.
Approval rests on the Phase 3 CORE and CORE2 studies. In patients with baseline triglyceride levels of at least 880 mg/dL, Tryngolza cut triglycerides by up to 73% at six months versus placebo (p
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma